I have three DEXA scans on the same scanner at twelve-week intervals, fasted, same time of day.
I would like to know whether this claim survives contact with evidence.
If the answer is "nobody has tested that", I would like that stated so I can stop looking.
What would count as evidence here, and does it exist?
Mechanically, planning the maintenance structure before stopping is the intervention with the most leverage.
Five half-lives is the conventional point at which exposure is negligible. For semaglutide at roughly one week that is about five weeks; for tirzepatide at about five days it is around three and a half weeks; for liraglutide at thirteen hours it is under three days.
| Method | Measures | Sensitive to | Least significant change |
|---|---|---|---|
| DEXA | Three-compartment by attenuation | Hydration, positioning | ~2–3 % regional lean |
| BIA (consumer) | Impedance, modelled | Hydration, food, temperature | Not usable at this timescale |
| Air displacement | Two-compartment by density | Lung volume, hair, clothing | ~1–2 % fat mass |
| Tape and scale | Circumference, mass | Technique | Surprisingly usable as a trend |
The relevant detail is that restarting after a gap generally requires re-titration rather than resumption at the previous dose, because tolerance to the gastrointestinal effects is lost.
Loss of tolerance to gastrointestinal effects during a treatment gap is the reason re-titration is advised on restarting.
If other glucose-lowering medication is on board, that is the urgent part of this question.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe short version: appetite returns over weeks, weight follows over months, and the trial evidence on withdrawal is unambiguous.
Gastrointestinal effects resolve as exposure falls, generally faster than the appetite effect because tolerance had already reduced them.
A structured maintenance plan — activity, protein, monitoring, contact — should be in place before the last dose rather than assembled afterwards.
No dependence or withdrawal syndrome has been described for this class in the pharmacovigilance record, which is consistent with the mechanism.
No withdrawal syndrome; the appetite comes back, which is not the same thing.
edited 4 Sept 2024 by m_haraldsen — corrected a unit error in the worked example
Answering this needs the agent, since half-lives across the class span from about thirteen hours to about a week.
Appetite returns progressively rather than abruptly, tracking the falling exposure, which is why the first month after stopping often feels manageable and the second does not.
In practice, weight regain in withdrawal trials begins within weeks and continues for a year or more, which is the timescale over which a maintenance plan has to work.
Half-life figures for the agents in this class are published in their regulatory pharmacokinetic reviews and are the basis for any clearance estimate.
Re-titrate on restarting. Tolerance is lost quickly.
Anyone on glucose-lowering medication has a dose question on stopping, which is the one genuinely urgent part of this.
For anyone on insulin or a sulfonylurea, stopping a glucose-lowering agent changes the requirement for the others, and that is a prescriber conversation rather than a self-managed one.
The caveat is that stopping in the presence of other glucose-lowering medication is a prescriber decision, not a forum one.
Build the maintenance structure before the last dose, not after.
The honest answer is that there is no withdrawal syndrome in the pharmacological sense and there is a very reliable return of appetite.
There is no dependence and no withdrawal syndrome in the pharmacological sense. What returns is the underlying appetite regulation, which is a different thing.
Nothing here is medical advice.
Five half-lives to negligible. Work it out for your agent and the timeline is obvious.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.